

# Innovus Pharma


## CORPORATE PROFILE

Headquartered in San Diego, Innovus Pharma is an emerging over-the-counter ("OTC") consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men's and women's health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application ("ANDA") products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.

9171 Towne Centre Drive, Ste 440 IR@InnovusPharma.com  
San Diego, CA 92122 T: (858) 964-5123  
Phone: (858) 964-5123  
Fax: (858) 249-7879  
<http://www.innovuspharma.com>  
[info@innovuspharma.com](mailto:info@innovuspharma.com)

## STOCK PERFORMANCE

Symbol	INN
Exchange	OTCQB
Market Cap.	14.39m
52 Week Range	0.078 - 0.39
Close	0.085
Volume	2
Shares Outstanding	164,434,088
As of Nov 17, 2017 3:59 pm	



## MANAGEMENT TEAM

**Bassam Damaj, Ph.D.** - President and Chief Executive Officer

**Randy Berholtz, MBA/JD** - Executive Vice President, Corporate Development and General Counsel

**Rauly Gutierrez, CPA** - Vice President, Finance and Principal Financial and Accounting Officer

## RECENT HEADLINES

[Nov 17, 2017 - SeeThruEquity Issues Update on Innovus Pharmaceuticals \(INN\) with a Price Target of \\$0.65](#)

[Nov 16, 2017 - Innovus Pharmaceuticals Strengthens Its Intellectual Property Portfolio with New Patent for Its Sensum+® Product in Mexico](#)

[Nov 14, 2017 - Innovus Pharmaceuticals Reports Nine Month Net Revenue of \\$6.4 million and Net Loss Decrease of 51.6% Compared to the Same Period in 2016](#)

[Nov 14, 2017 - Innovus Pharma Launches FlutiCare\(TM\) OTC Nasal Spray Allergy Relief in the U.S.](#)

[Nov 13, 2017 - Innovus Pharma Enters the \\$11 Billion Glucose Monitoring Market with FDA-Cleared Products via an Expanded Agreement with ACON Laboratories, Inc.](#)

## PAST EVENTS

Apr 30, 2016 - The San Diego Union Tribune Successful Aging Expo